Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06768476 | CART123 + Ruxolitinib in Relapsed/Refractory AML | PHASE1 | ACTIVE NOT_RECRUITING | 12 | — | — | Feb 28, 2025 | Mar 1, 2045 | Jan 16, 2026 | 1 | United States |
Type, frequency, severity, and attribution of AEs/SAEs, including the incidence and severity of IEC-associated adverse events.
| Arm | Type | Description |
|---|---|---|
| Arm A: DL1 | EXPERIMENTAL | * LD Chemo: Day -6 to Day -4 (±1d) * Ruxolitinib: Daily beginning on Day -6 (±1d) through D14 post CART123 infusion. * CART123 Cells: Single infusion on Day 0 |
| Arm A: DL-1 | EXPERIMENTAL | * LD Chemo: Day -6 to Day -4 (±1d) * Ruxolitinib: Daily beginning on Day -6 (±1d) through D14 post CART123 infusion. * CART123 Cells: Single infusion on Day 0 |
| Arm B: DL-1 | EXPERIMENTAL | * LD Chemo: Day -6 (-1d) to Day -2 (-1d) * Venetoclax: Day -6 (-1d) through Day +7 - Day +14 post-CART123 infusion * Ruxolitinib: Daily beginning on Day -1 through Day +7 post CART123 infusion. * CART123 Cells: Single infusion on Day 0 |
| Name | Type | Description |
|---|---|---|
| CART123 Cells | BIOLOGICAL | 1.3x10\^8 CART123 cells |
| Ruxolitinib 10 MG | DRUG | Twice Daily |
| Ruxolitinib 5 MG | DRUG | Twice Daily |
Inclusion Criteria: * 1\. Signed informed consent form 2. Male or female age ≥ 18 years. 3. Patients with active acute myeloid leukemia (AML) with no available curative treatment options using currently available therapies. This is specifically defined as one of the following: 1. AML that has no...